Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616507 | 0.82 | LMNA (0.40) | LMNARECQLALDH1A1MEN1KMT2A | |
| SCHEMBL10976101 | 0.80 | LMNA (0.38) | LMNARECQLALDH1A1MEN1KMT2A | |
| SCHEMBL30262284 | 0.78 | LMNA (0.38) | LMNARECQLALDH1A1MEN1KMT2A | |
| SCHEMBL17127790 | 0.74 | SMN1; SMN2 (0.38) | LMNARECQLALDH1A1MEN1KMT2A | |
| SCHEMBL10147308 | 0.73 | LMNA (0.40) | LMNARECQLALDH1A1MEN1KMT2A | |
| SCHEMBL12352344 | 0.72 | LMNA (0.42) | LMNARECQLALDH1A1MEN1KMT2A | |
| SCHEMBL12970324 | 0.71 | ESR1 (0.37) | LMNAIKBKBCHUK | |
| SCHEMBL128435 | 0.68 | DDB1 (0.42) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL20600776 | 0.68 | PRPS1 (0.44) | LMNARECQLALDH1A1KDM4EGLA | |
| SCHEMBL21608524 | 0.68 | SMN1; SMN2 (0.46) | LMNARECQLALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011001-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011001-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8790919-B2 | Compositions and methods for optimizing cleavage of RNA by RNase H | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8790919-B2 | Compositions and methods for optimizing cleavage of RNA by RNase H | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2700720-A2 | Compositions and methods for optimizing cleavage of RNA by RNASE H | Isis Pharmaceuticals, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | SMITH LARRY J (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | SMITH LARRY J (US) | 2012-06-21 | — | — | US | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | RNASEH1, NSUN3, RNASEL | LMNA 453/4885RECQL 742/4885ALDH1A1 3259/4885 |
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | CKMT1A; CKMT1B, ATF4, NFATC1 | LMNA 299/4885RECQL 1471/4885ALDH1A1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.